Muscarinic receptor subtypes insubtypes in Airways

doi:10.1016/0165-6147(88)90069-7

Trends in Pharmacological Sciences

Volume 9, Issue 11, November 1988, Pages 412-416

https://doi.org/10.1016/0165-6147(88)90069-7 Get rights and content

Abstract

Subtypes of muscarinic receptor have recently been shown to exist in the airways of several species, including humans. M₁ receptors may be present in sympathetic nerves and parasympathetic ganglia. M₂ receptors on cholinergic nerves (autoreceptors) and M₃ receptors on smooth muscle and mucus glands. Peter Barnes, Philippe Minette and Jenny Maclagan discuss the possible role of these subtypes of receptor and speculate on the future clinical implications of these discoveries.

References (39)

T.I. Bonner et al.
Neuron
(1988)
J.W. Bloom et al.
Eur. J. Pharmacol.
(1987)
J.H. Ashe et al.
Neuropharmacology
(1984)
A.D. Michel et al.
Eur. J. Pharmacol.
(1988)
H. Kilbinger et al.
Neurosci. Lett.
(1980)
R.M. Eglen et al.
J. Autan. Pharmacol.
(1986)
T. Kubo
Nature
(1986)
E.G. Peralta
Science
(1987)
P.J. Barnes
Am. Rev. Respir. Dis.
(1986)

P.J. Bames

Am. Rev. Respir. Dis.

(1987)

R. Hammer et al.

Nature

(1980)

P. Hammer et al.

Life Sci.

(1982)

B.I. Hirschowitz et al.

J. Pharmacol. Exp. Ther.

(1983)

K.C. Beck et al.

Am. Rev. Respir. Dis.

(1987)

B.M. Grandordy et al.

J. Pharmacol. Exp. Ther.

(1986)

J.M. Madison et al.

Am. Rev. Respir. Dis.

(1987)

K. Sertd et al.

Int. J. Clin. Pharmacol. Ther. Toxicol.

(1986)

M. Cazzola et al.

Int. J. Pharmacol. Ther. Toxicol.

(1987)

Cited by (77)

Airway Pharmacology
2013, Benumof and Hagberg's Airway Management
Airway Pharmacology
2012, Benumof and Hagberg's Airway Management: Third Edition
Innervation of equine airways
2002, Pulmonary Pharmacology and Therapeutics
Equine obstructive pulmonary disease (COPD), or heaves or recurrent airway obstruction, is a common equine pulmonary disease similar to human asthma and/or CODP. Since bronchospasm and inflammation are the key features in heaves, the purpose of this paper is to review the contribution of neural mechanism that may be relevant to this disease. Equine airway receive cholinergic and adrenergic innervation, as well as observed in many species. It was suggested that the autonomic neural control in asthma might be defective with an imbalance between excitatory and inhibitory pathways, resulting in excessively twitchy airways. Moreover, the recognition that, in addition to classical adrenergic and cholinergic pathway there are non-adrenergic–non-cholinergic inhibitory (iNANC) and excitatory (eNANC) innervation and many mediators, which have potent effects on airway function, has revived interest in neural control of airway.
The role of anticholinergics in acute asthma treatment: An evidence-based evaluation
2002, Chest
The role for anticholinergic medications in acute asthma is not well-defined. Thus, the use of therapy with anticholinergics and β₂-agonists, either simultaneously or in sequence, has produced positive as well as negative results in trials. Therefore, the current recommendations for the use of these drugs in the emergency department (ED) and hospital management of asthma exacerbations are not precise. This review answers the following question: what level of evidence is available in the literature to support the use of anticholinergic medications in combination with β₂-agonists in acute asthma patients? We limited the search on our therapy question to systematic reviews of randomized trials and/or randomized controlled trials not included in the reviews. After an extensive review of the most relevant evidence, the following conclusions may be emphasized. (1) The use of multiple doses of ipratropium bromide are indicated in the ED treatment of children and adults with severe acute asthma. The studies reported a substantial reduction in hospital admissions (30 to 60%; number needed to treat, 5 to 11) and significant differences in lung function favoring the combined treatment. No apparent increase in the occurrence of side effects was observed. (2) The use of single-dose protocols of ipratropium bromide with β₂-agonist treatment produced, particularly in children with more severe acute asthma, a modest improvement in pulmonary function without reduction in hospital admissions; in adults, the data showed a similar increase in pulmonary function with an approximately 35% reduction in the hospital admission rate. In patients with mild-to-moderate acute asthma, there is no apparent benefit from adding a single dose of an anticholinergic medication.
Pharmacology of bronchodilators used in the treatment of COPD
2000, Respiratory Medicine
Low frequency-dependent mechanism of the M<inf>2</inf> receptor function on vagally mediated bronchoconstriction in rabbits in vivo
1999, Life Sciences
The present study was carried out to investigate whether there is the difference between low and high frequencies of vagal stimulation on the functional appearance of M₂ receptors in the rabbit. The animals were anesthetized, artificially ventilated and bilaterally vagotomized. Bilateral vagus nerve stimulation (5 to 30 Hz) for 30 sec caused bronchoconstriction (measured as an increase in R_L and a decrease in Cdyn) in a frequency-dependent manner. The bronchoconstriction evoked by ACh injection (1 and 3 $μg kg$ ) was dose-dependent. Although administration of methoctramine (50 and 300 $μg kg$ ), a selective M₂ receptor antagonist, had no significant effect on ACh-induced bronchoconstriction, methoctramine dose-dependently augmented the R_L and Cdyn responses to vagal stimulation at 5–15 Hz but did not potentiate bronchoconstrictive responses to the stimulation at 30 Hz. Administration of [D-Pro², D-Try^7,9]-SP (0.5 $mg kg$ , a selective tachykinin receptor antagonist) that had no significant effect on the R_L and Cdyn responses to vagal stimulation (5–15 Hz) attenuated the bronchoconstrictive response to the stimulation at 30 Hz. Conversely, thiorphan (2 $mg kg$ , a neutral endopeptidase inhibitor) potentiated the bronchoconstriction evoked by vagal stimulation at 30 Hz only. These results suggest that M₂ receptors function as the inhibitory receptors in the bronchoconstrictive response to vagal stimulation at the lower frequencies (5–15 Hz), but that the M₂ receptor antagonism is diminished when vagal stimulation at a higher frequency (30 Hz) results in the release of SP from the lungs.

View all citing articles on Scopus

View full text

Trends in Pharmacological Sciences

Muscarinic receptor subtypes insubtypes in Airways

Abstract

Neuron

Eur. J. Pharmacol.

Neuropharmacology

Eur. J. Pharmacol.

Neurosci. Lett.

J. Autan. Pharmacol.

Nature

Science

Am. Rev. Respir. Dis.

Am. Rev. Respir. Dis.

Nature

Life Sci.

J. Pharmacol. Exp. Ther.

Am. Rev. Respir. Dis.

J. Pharmacol. Exp. Ther.

Am. Rev. Respir. Dis.

Int. J. Clin. Pharmacol. Ther. Toxicol.

Int. J. Pharmacol. Ther. Toxicol.